<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36048910</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>36</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Lots of long COVID treatment leads, but few are proven.</ArticleTitle><Pagination><StartPage>e2213524119</StartPage><MedlinePgn>e2213524119</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2213524119</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2213524119</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaffer</LastName><ForeName>Leah</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>1</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36048910</ArticleId><ArticleId IdType="pmc">PMC9456722</ArticleId><ArticleId IdType="doi">10.1073/pnas.2213524119</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mahase E., Covid-19: What do we know about &#x201c;long covid&#x201d;? BMJ 370, m2815 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L., et al. , Post-COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years &#x2014; United States, March 2020&#x2013;November 2021. MMWR Morb. Mortal. Wkly. Rep. 71, 713&#x2013;717 (2022).</Citation></Reference><Reference><Citation>Groff D., et al. , Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw. Open 4, e2128568 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., et al. , Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 18, e1003773 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo S. M., et al. , Factors associated with post-acute sequelae of SARS-CoV-2 (PASC) after diagnosis of symptomatic COVID-19 in the inpatient and outpatient setting in a diverse cohort. J. Gen. Intern. Med. 37, 1988&#x2013;1995 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989256</ArticleId><ArticleId IdType="pubmed">35391623</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., et al. , Health outcomes in people 2 years after surviving hospitalization with COVID-19: A longitudinal cohort study. Lancet Respir. Med., 10.1016/S2213-2600(22)00126-6 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A. D., VanElzakker M. B., Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 12, 698169 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Blish C. A., Sallusto F., Iwasaki A., The immunology and immunopathology of COVID-19. Science 375, 1122&#x2013;1127 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, et al. , SARS-CoV-2 infection and persistence throughout the human body and brain. 10.21203/rs.3.rs-1139035/v1 (20 December 2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1139035/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles V. G., et al. , Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 383, 590&#x2013;592 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartard C., et al. , Multiorgan and vascular tropism of SARS-CoV-2. Viruses 14, 515 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8955556</ArticleId><ArticleId IdType="pubmed">35336922</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A., et al. , Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y) 3, 371&#x2013;387.e9 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Trypsteen W., Van Cleemput J., Snippenberg W. V., Gerlo S., Vandekerckhove L., On the whereabouts of SARS-CoV-2 in the human body: A systematic review. PLoS Pathog. 16, e1009037 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7679000</ArticleId><ArticleId IdType="pubmed">33125439</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng LN, Bonilla HF, Shafer RW, Miglis MG, Yang PC, Case report of breakthrough long COVID and the use of nirmatrelvir-ritonavir. 10.21203/rs.3.rs-1443341/v1 (15 March 2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1443341/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., et al. ; Irish COVID-19 Vasculopathy Study (iCVS) investigators, Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost. 19, 2546&#x2013;2553 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>do Campo J., Taylor V., Clinical improvement in patients with ME/CFS with synergistic effect of colchicine and spironolactone targeting inhibition of inflammasome activity. Intern. Med. J. 52 (suppl. 1), 4&#x2013;19 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Treatment Guidelines Panel, COVID-19 treatment guidelines: Colchicine. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/colchicine/. Accessed 1 July 2022.</Citation></Reference><Reference><Citation>Patterson B. K., et al. , Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front. Immunol. 12, 746021 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, et al. , Targeting the monocytic-endothelial-platelet axis with maraviroc and pravastatin as a therapeutic option to treat long COVID/post-acute sequelae of COVID (PASC). 10.21203/rs.3.rs-1344323/v1 (10 February 2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1344323/v1</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation> IncellDx awarded patent for use of CCR5 antagonist maraviroc in treatment of COVID-19. https://www.businesswire.com/news/home/20211123005960/en/IncellDx-Awarded-Patent-for-Use-of-CCR5-Antagonist-Maraviroc-in-Treatment-of-COVID-19. Businesswire. Accessed 1 July 2022.</Citation></Reference><Reference><Citation>Page M. J., Kell D. B., Pretorius E., The role of lipopolysaccharide-induced cell signalling in chronic inflammation. Chronic Stress (Thousand Oaks) 6, 24705470221076390 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8829728</ArticleId><ArticleId IdType="pubmed">35155966</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L. M., et al. , SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci. Rep. 41, BSR20210611 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Combined triple treatment of fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) can resolve their persistent symptoms. 10.21203/rs.3.rs-1205453/v1 (28 December 2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1205453/v1</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan C. M., et al. , Oral famotidine versus placebo in non-hospitalised patients with COVID-19: A randomised, double-blind, data-intense, phase 2 clinical trial. Gut 71, 879&#x2013;888 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8844971</ArticleId><ArticleId IdType="pubmed">35144974</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., et al. , Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm. Mol. Med. 28, 57 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9109205</ArticleId><ArticleId IdType="pubmed">35578169</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornero C., et al. , Non-invasive vagus nerve stimulation for COVID-19: Results from a randomized controlled trial (SAVIOR I). Front. Neurol. 13, 820864 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9028764</ArticleId><ArticleId IdType="pubmed">35463130</ArticleId></ArticleIdList></Reference><Reference><Citation>Albarrac&#xed;n D., et al. , ( 2022) Getting to and sustaining the next normal: A roadmap for living with COVID. https://www.covidroadmap.org Accessed 1 July 2022.</Citation></Reference><Reference><Citation> FACT SHEET: The Biden Administration accelerates whole-of-government effort to prevent, detect, and treat long COVID. https://www.whitehouse.gov/briefing-room/statements-releases/2022/04/05/fact-sheet-the-biden-administration-accelerates-whole-of-government-effort-to-prevent-detect-and-treat-long-covid/. The White House. Accessed 1 July 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>